Autoimmune liver serology: Current diagnostic and clinical challenges

World Journal of Gastroenterology

Volumn 14, Issue 21, 2008, Pages 3374-3387

  Bogdanos, Dimitrios P ^a   Invernizzi, Pietro ^b   Mackay, Ian R ^c   Vergani, Diego ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Auto antibody; Autoantigen; Autoimmune hepatitis; Liver disease; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIPERINUCLEAR FACTOR; ASIALOGLYCOPROTEIN RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; LIVER CYTOSOL 1 ANTIBODY; LIVER CYTOSOL 1 ANTIGEN; LIVER KIDNEY MICROSOME ANTIBODY; LKM1 ANTIGEN; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; MITOCHONDRION ANTIGEN; NEUTROPHIL CYTOPLASMIC ANTIBODY; NEUTROPHIL NUCLEAR ANTIBODY; PYRUVATE DEHYDROGENASE COMPLEX; RECEPTOR ANTIBODY; RECOMBINANT ANTIGEN; SMOOTH MUSCLE ANTIBODY; SMOOTH MUSCLE ANTIGEN; SMOOTH MUSCLE AUTOANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE HEPATITIS TYPE 1; AUTOIMMUNE HEPATITIS TYPE 2; CELL NUCLEUS INCLUSION BODY; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE; NUCLEAR PORE COMPLEX; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; SERODIAGNOSIS;

EID: 54349118451     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3374     Document Type: Article

References (154)

1. Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003; 7: 759-777, vi
2. Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007; 27: 161-172
3. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120: 239-249
4. Selmi C, Mackay IR, Gershwin ME. The immunological milieu of the liver. Semin Liver Dis 2007; 27: 129-139
5. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
6. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, Vergani D, Mieli-Vergani G. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547
7. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-553
8. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, Heaton ND, Vergani D, Mieli-Vergani G. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998; 351: 409-413
9. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-1273
10. Miescher P, Fauconnet M. [Absorption of L. E. factor by isolated cell nuclei.] Experientia 1954; 10: 252-253
11. Hargraves M, Richmond H, Morton R. Presentation of two bone marrow elements: The "tart" cells and the "L.E" cell. Mayo Clin Proc 1948; 27: 25-28
12. Robbins WC, Holman HR, Deicher H, Kunkel HG. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol Med 1957; 96: 575-579
13. Holman H, Deicher HR. The reaction of the lupus erythematosus (L.E.) cell factor with deoxyribonucleoprotein of the cell nucleus. J Clin Invest 1959; 38: 2059-2072
14. Cowling DC, Mackay IR, Taft LI. Lupoid hepatitis. Lancet 1956; 271: 1323-1326
15. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet 1959; 1: 65-69
16. Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet 1965; 2: 878-879
17. Whittingham S, Irwin J, Mackay IR, Smalley M. Smooth muscle autoantibody in "autoimmune" hepatitis. Gastroenterology 1966; 51: 499-505
18. Bottazzo GF, Florin-Christensen A, Fairfax A, Swana G, Doniach D, Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 1976; 29: 403-410
19. Gabbiani G, Ryan GB, Lamelin JP, Vassalli P, Majno G, Bouvier CA, Cruchaud A, Luscher EF. Human smooth muscle autoantibody. Its identification as antiactin antibody and a study of its binding to "nonmuscular" cells. Am J Pathol 1973; 72: 473-488
20. Lidman K, Biberfeld G, Fagraeus A, Norberg R, Torstensson R, Utter G, Carlsson L, Luca J, Lindberg U. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976; 24: 266-272
21. Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol 1979; 38: 621-628
22. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973; 15: 331-344
23. Rizzetto M, Bianchi FB, Doniach D. Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology 1974; 26: 589-601
24. Smith MG, Williams R, Walker G, Rizzetto M, Doniach D. Hepatic disorders associated with liver-kidney microsomal antibodies. Br Med J 1974; 2: 80-84
25. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26: 1054-1066
26. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy VG, Grippon P. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333-1339
27. Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988; 168: 801-806
28. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 1066-1072
29. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 85: 8256-8260
30. Crivelli O, Lavarini C, Chiaberge E, Amoroso A, Farci P, Negro F, Rizzetto M. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol 1983; 54: 232-238
31. Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114: 324-328
32. Boccaccio F, Attali P, Nataf J, Ink O, Fabre M, Pelletier G. [Acute hepatitis caused by dihydralazine] Gastroenterol Clin Biol 1987; 11: 614
33. Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Buschenfelde KH, Meyer UA, Eichelbaum M. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 1990; 12: 127-132
34. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, Guengerich FP, Beaune PH. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990; 85: 1967-1973
35. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 1662-1666
36. Lenzi M, Manotti P, Muratori L, Cataleta M, Ballardini G, Cassani F, Bianchi FB. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995; 36: 749-754
37. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643-649
38. Muratori L, Sztul E, Muratori P, Gao Y, Ripalti A, Ponti C, Lenzi M, Landini MP, Bianchi FB. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001; 34: 494-501
39. Mackay IR. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. N Engl J Med 1958; 258: 185-188
40. Asherson GL, Dumonde DC. Characterization of auto-antibodies produced in the rabbit by the injection of rat liver. Br J Exp Pathol 1962; 43: 12-20
41. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological Tests in Diagnosis of Primary Biliary Cirrhosis. Lancet 1965; 1: 827-831
42. Berg PA, Doniach D, Roitt IM. Mitochondrial antibodies in primary biliary cirrhosis. I. Localization of the antigen to mitochondrial membranes. J Exp Med 1967; 126: 277-290
43. Berg PA, Muscatello U, Horne RW, Roitt IM, Doniach D. Mitochondrial antibodies in primary biliary cirrhosis. II. The complement fixing antigen as a component of mitochondrial inner membranes. Br J Exp Pathol 1969; 50: 200-208
44. Berg PA, Roitt IM, Doniach D, Cooper HM. Mitochondrial antibodies in primary biliary cirrhosis. IV. Significance of membrane structure for the complement-fixing antigen. Immunology 1969; 17: 281-293
45. Berg PA, Roitt IM, Doniach D, Horne RW. Mitochondrial antibodies in primary biliary cirrhosis. 3. Characterization of the inner-membrane complement fixing antigen. Clin Exp Immunol 1969; 4: 511-525
46. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525-3531
47. Yeaman SJ, Fussey SP, Danner DJ, Jamos OF, Mutimor DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1: 1067-1070
48. Leung PS, Coppel RL, Ansari A, Munoz S, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 61-69
49. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-294
50. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18: 1-9
51. Wies I, Brunner S, Henninger J, Heykel J, Kanzler S, Meyer zum Buschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355:1510-1515
52. McFarlane IG, Hegarty JE. McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2: 954-956
53. McFarlane IG, McFarlane BM, Major GN, Tolley P, Williams R. Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 1984; 55: 347-354
54. Weller TH, Coons AH. Fluorescent antibody studies with agents of varicella and herpes zoster propagated in vitro. Proc Soc Exp Biol Med 1954; 86; 789-794
55. Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, Nishioka M, Penner E. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41; 677-683
56. Toolan HW. Transplantable human neoplasms maintained in cortisone-treated laboratory animals: H.S. No. 1; H.Ep. No. 1; H.Ep. No. 2; H.Ep. No. 3; and H.Emb.Rh. No. 1. Cancer Res 1954; 14: 660-666
57. Moore AE, Sabachewsky L, Toolan HW. Culture characteristics of four permanent lines of human cancer cells. Cancer Res 1955; 15: 598-602
58. Szostecki C, Guldner HH, Will H. Autoantibodies against "nuclear dots" in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 71-78
59. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 199; 17: 79-90
60. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-1295
61. Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003; 125: 1476-1479
62. Hannam S, Bogdanos DP, Davies ET, Hussain MJ, Portmann BC, Mieli-Vergani G, Vergani D. Neonatal liver disease associated with placental transfer of anti-mitochondrial antibodies. Autoimmunity 2002; 35: 545-550
63. Muratori L, Cataleta M, Muratori P, Manotti P, Lenzi M, Cassani F, Bianchi FB. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. J Immunol Methods 1995; 187: 259-264
64. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem GK, The TH. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-429
65. Hagen EC, Andrassy K, Chernok E, Daha MR, Gaskin G, Gross W, Lesavre P, Ludemann J, Pusey CD, Rasmussen N. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods 1993; 159: 1-16
66. Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T, Spengler U. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998; 28: 332-340
67. Terjung B, Spengler U, Sauerbruch T, Worman HJ. "A typical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119: 310-322
68. Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol 2001; 126: 37-46
69. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmuno hepatitis. Hepatology 1996; 24: 1068-1073
70. Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006; 59: 280-284
71. Frenzel C, Herkel J, Luth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastrointerol 2006; 101: 2731-2736
72. Liaskos C, Bogdanos DP, Davies ET, Dalekos GN. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 2007; 60: 107-108
73. Zamanou A, Tsirogianni A, Terzoglou C, Balafas A, Economidou I, Lyinberi P. Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in liver diseases: a comparison of classical indirect immunofluorescence with ELISA. J Clin Lab Anal 2002; 16: 194-201
74. Granito A, Muratori P, Muratori L, Georgios P, Lenzi M, Bianchi FB. Antifilamentous actin antibodies by ELISA for the diagnosis of type 1 autoimmune hepatitis. Am J Gastroenterol 2007; 102: 1131-1132
75. Villalta D, Bizzaro N, Da Re M, Tozzoli R, Komorowski L, Tonutti E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity 2008; 41: 105-110
76. Bogdanos DP, Mieli-Vergani G, Vergani D. Liver-kidney microsomal antibody-positive autoimmune hepatitis in the United States. Am J Gastroenterol 2001; 96: 3447-3448
77. Ma Y, Gregorio G, Gaken J, Muratori L, Bianchi FB, Mieli-Vergani G, Vergani D. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type 1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection. J Hepatol 1997; 26: 1396-1402
78. Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, Muratori L, Tsantoulas D, Mieli- Vergani G, Bianchi FB, Vergani D. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004; 17: 83-92
79. Ma Y, Peakman M, Lobo-Yeo A, Wen L, Lenzi M, Gaken J, Farzaneh F, Mieli-Vergani G, Bianchi FB, Vergani D. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clin Exp Immunol 1994; 97: 94-99
80. Muratori L, Lenzi M, Ma Y, Cataleta M, Mieli-Vergani G, Vergani D, Bianchi FB. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hapatitis and hepatitis C virus related liver disease. Gut 1995; 37: 406-412
81. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Durr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-664
82. Volkmann M, Martin L, Baurle A, Heid H, Strassburg CP, Trautwein C, Fiehn W, Manns MP. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001; 33: 591-596
83. Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle PR, Lohse AW. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-264
84. Ballot E, Bruneel A, Labas V, Johanet C. Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin Chem 2003; 49: 634-643
85. Bogdanos DP, Bianchi I, Ma Y, Mitry RR, Mieli-Vergani G, Vergani D. Targets of antibodies to soluble liver antigen in patients with autoimmune hepatitis. Clin Chem 2004; 50: 682-683; author reply 683-684
86. Vitozzi S, Djilali-Saiah I, Lapierre P, Alvarez F. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 2002; 35: 485-492
87. Xu XM, Carlson BA, Mix H, Zhang Y, Saira K, Glass RS, Berry MJ, Gladyshev VN, Hatfield DL. Biosynthesis of selenocysteine on its tRNA in eukaryotes. PLoS Biol 2007; 5: e4
88. Moteki S, Leung PS, Coppel RL, Dickson ER, Kaplan MM, Munoz S, Gershwin ME. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 1996; 24: 97-103
89. Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Gershwin ME. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45: 659-665
90. Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007; 27: 378-387
91. Janka C, Selmi C, Gershwin ME, Will H, Sternsdorf T. Small ubiquitin-related modifiers: A novel and independent class or autoantigens in primary binary cirrhosis. Hepatology 2005; 41: 609-616
92. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, Rodrigo L, Linares A, Fuentes D, Bianchi FB. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 431-437
93. Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, Burroughs AK, Vergani D. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis 2003; 35: 801-805
94. Bogdanos DP, Liaskos C, Pares A, Norman G, Rigopoulou EI, Caballeria L, Dalekos GN, Rodes J, Vergani D. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007: 45: 1583; author reply 1583-1583; author reply 1584
95. Bogdanos DP, Pares A, Rodes J, Vergani D. Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain. Am J Gastroenterol 2004; 99: 763-764: author reply 765
96. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, Saoshiro T, Harada H, Sodeyama T, Hayashi S, Masumoto A, Sando T, Yamamoto T, Sakai H, Kobayashi M, Muro T, Koga M, Shums Z, Norman GL, Ishibashi H. Anti-gp210 and anti-centromere antibodies are different risk factors for the progreession of primary biliary cirrhosis. Hepatology 2007; 45: 118-127
97. Bauer A, Habior A. Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis. J Clin Lab Anal 2007; 21: 227-231
98. Wesierska-Gadek J, Klima A, Komina O, Ranftler C, Invernizzi F, Penner E. Characterization of autoantibodies against of anti-p62 nucleoporin antibodies. Ann N Y Acad Sd 2007; 1109: 519-530
99. Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003; 98: 241-243
100. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in Primary biliary cirrhosis. Semin Liver Dis 2005; 25: 298-310
101. Terjung B, Gottwein J, Muennich M, Muennich M, Gottwein J, Sauerbruch T, Spengler U. Identifizierung des Zielantigens atypischer p-ANCA bei autoimmunen Lebererkrankungen als Protein der Tubulin-beta Genfamilie. Z Gastroenterol 2005; 43: Abstract
102. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159-1166
103. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-417
104. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 1266-1271
105. Bogdanos DP, Mieli-Vergani G, Vergani D. Non-organspecific autoantibodies in children with chronic hepatitis C virus infection. Clin Infect Dis 2004; 38: 1505; author reply 1505-1506
106. Bogdanos DP, Mieli-Vergani G, Vergani D. Non-organspecific autoantibodies in hepatitis C virus infection: do they matter? Clin Infect Dis 2005; 40: 508-510
107. Bogdanos DP, Mieli-Vergani G, Vergani D. Virus, liver and autoimmunity. Dig Liver Dis 2000; 32: 440-446
108. Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K, Miyakawa H, Norman GL, Lee W, Gershwin ME. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 2007; 46: 1436-1442
109. Bogdanos DP, Liaskos C, Rigopoulou EI, Dalekos GN. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. Clin Chim Acta 2006; 373: 183-184; author reply 185
110. Liaskos C, Bogdanos DP, Rigopoulou EI, Dalekos GN. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art or facts or an artifact? J Gastroenterol Hepatol 2007; 22: 454-455
111. Bernal W, Meda F, Ma Y, Bogdanos DP, Vergani D. Disease-specific autoantibodies in patients with acute liver failure: the King's College London Experience. Hepatology 2008; 47: 1096-1097; author reply 1097
112. Butler P, Hamilton-Miller J, Baum H, Burroughs AK. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis? Biochem Mol Biol Int 1995; 35: 473-485
113. Klein R, Wiebel M, Engelhart S, Berg PA. Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis. Clin Exp Immunol 1993; 92: 308-316
114. Gilburd B, Ziporen L, Zharhary D, Blank M, Zurgil N, Scheinberg MA, Guedes LH, Gershwin ME, Shoenfeld Y. Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol 1994; 14: 14-19
115. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733-1740
116. Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS, Dickson ER, Homburger HA. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997; 2: 6-11
117. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 2: 1090-1095
118. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002; 35: 515-519
119. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 19977; 26: 5677-572
120. Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Buschenfelde KH, Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 19993; 19; 55-63
121. Kanzler S, Weidemann C, Gerken G, Lohr HE, Gaile PR, Meyer zum Buschenfelde KH, Lohse AW. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635-640
122. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002; 35: 475-483
123. Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S. Homberg JC. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16: 892-898
124. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/ kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 721-726
125. Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007; 27: 1226-1231
126. Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, Maggioni M, Meroni PL, Penner E, Wesierska-Gadek J. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001; 34: 366-372
127. Miyachi K, Hankins RW, Matsushima H, Kikuchi F, Inomata T, Horigome T, Shibata M, Onozuka Y, Ueno Y, Hashimoto E, Hayashi N, Shibuya A, Amaki S, Miyakawa H. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmune 2003; 20: 247-254
128. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481-1489
129. Wesierska-Gadek J, Penner F, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43: 1135-1144
130. Yang WH, Yu JH, Nakajima A, Nenberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2: 1116-1122
131. Vergani D, Mieli-Vergani G. The impact of autoimmunity on hepatocytes. Semin Liver Dis 2007; 27: 140-151
132. Bogdanos DP, Baum H, Sharma UC, Grasso A, Ma Y, Burroughs AK, Vergani D. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol 2002; 36: 14-21
133. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41: 31-37
134. Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, Rigopoulou E, Montalto P, Davies ET, Burroughs AK, Vergani D. Microbial mimics are major targets of crossre-activity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004; 40: 31-39
135. Bogdanos DP, Baum H, Gunsar F, Arioli D, Polymeros D, Ma Y, Burroughs AK, Vergani D. Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity. Scand J Gastroenterool 2004; 39: 981-987
136. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatollogy 2005; 42; 458-465
137. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225-232
138. Bogdanos DP, Koutsoumpas A. Baum H. Vergani D. Borrelia Burgdorferi; a new self-mimicking trigger in primary biliary cirrhosis. Dig Liver Dis 2006; 38: 781-782; author reply 782-783
139. Bogdanos DP, McFarlane IG. Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmunity. J Hepatol 2003; 39: 860-863
140. Bogdanos DP, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, Burroughs AK, Rodes J, Vergani D. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun 2004; 22: 353-362
141. Bogdanos DP, Rigopoulou EI. Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. Diabetes Res Clin Pract 2007; 77: 155-156
142. Bogdanos DP, Vergani D. Origin of cross-reactive autoimmunity in primary biliary cirrhosis. Liver Int 2006; 26: 633-635
143. Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, O'Donnell B, Aitken J, Carman W, Neuberger J, Mason A. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci USA 2003; 100: 8454-8459
144. Mackay IR. The etiopathogenesis of autoimmunity. Semin Liver Dis 2005; 25: 239-250
145. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Kenny TP, Van De Water J, Nantz MH, Kurth MJ, Gershwin ME. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003; 38: 1250-1257
146. Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL. Immunoglobulin, on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 1987; 7: 307-315
147. Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000; 95: 3238-3241
148. Tan EM, Smolen JS, McDougal JS, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wiik A, Willson M, Koziol JA. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II potential for qnantitation of antibody content. J Rheumatol 2002; 29: 68-74
149. Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG, Slivka L, Koziol JA. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol 2003; 30: 2374-2381
150. Fritzler MJ, Wiik A, Fritzler ML, Barr SG. The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 2003; 5: 192-201
151. Rondeel JM, van Gelder W, van der Leeden H, Dinkelaar RB. Different strategies in the laboratory diagnosis of autoimmune disease: Immunofluorescence, enzyme-linked immunosorbent assay or both? Ann Clin Biochem 1999; 36(Pt 2): 189-195
152. Kerkar N, Ma Y, Davies ET, Cheeseman P, Mieli-Vergani G, Vergani D. Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays. J Clin Pathol 2002; 5: 906-909
153. Bogdanos DP, Gilbert D, Bianchi I, Leoni S, Mitry RR, Ma Y, Mieli-Vergani G, Vergani D. Antibodies to soluble liver antigen and alpha-enolase in patients with autoinumme hepatitis. J Autoimmune Dis 2004; 1: 4
154. Bogdanos DP, Vergani D, Muratori P, Muratori L, Bianchi FB. Specificity of anti-splOO antibody for primary biliary cirrhosis. Scand J Gastroenterol 2004; 39: 405-406; author reply 407